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Routinely recorded data held in electronic health records can be used to inform the conduct of Randomised 
Controlled Trials (RCTs). However, limitations with access and accuracy have been identified. Objective: Using 
epilepsy as an exemplar condition, we assessed the attributes and agreement of routinely recorded data 
compared to data collected using case report forms in a UK RCT assessing antiepileptic drug treatments for 
individuals newly diagnosed with epilepsy.   
Methods 
The case study RCT is the Standard and New Antiepileptic Drugs II (SANAD II) trial, a pragmatic, UK multicentre 
RCT assessing the clinical and cost effectiveness of antiepileptic drugs as treatments for epilepsy. Ninety eight 
of 470 eligible participants provided consent for access to routinely recorded secondary care data that were 
retrieved from NHS Digital Hospital Episode Statistics (N=71) and primary and secondary care data from The 
Secure Anonymised Information Linkage Databank (N=27). We assessed data items relevant to the 
identification of individuals eligible for inclusion in SANAD II, baseline and follow-up visits. The attributes of 
routinely recorded data were assessed including the degree of missing data. The agreement between routinely 
recorded data and data collected on case report forms in SANAD II was assessed using calculation of Cohen’s 
Kappa for categorical data and construction of Bland Altman plots for continuous data.      
Results 
There was a significant degree of missing data in the routine record for 15 of the 20 variables assessed, 
including all clinical variables. Agreement was poor for the majority of comparisons, including the assessments 
of seizure occurrence and adverse events. For example, only 23/62 (37%) participants had a date of first ever 
seizure identified in routine datasets. Agreement was satisfactory for date of prescription of antiepileptic drugs 
and episodes of healthcare resource use.  
Conclusions 
There are currently significant limitations preventing the use of routinely recorded data for participant 
identification and assessment of clinical outcomes in epilepsy, and potentially other chronic conditions. 
Further research is urgently required to assess the attributes, agreement, additional benefits, cost-
effectiveness and ‘optimal mix’ of routinely recorded data compared to data collected using standard methods 
such as case report forms at clinic visits for people with epilepsy.  
Trial Registration: Standard and New Antiepileptic Drugs II (SANAD II (EudraCT No: 2012-001884-64, registered 






There is great expectation that the analysis of routinely recorded healthcare data will provide rapid 
and efficient answers to healthcare questions, and be a vehicle to generate health and wealth for 
the UK, exemplified by the recent UKRI investment in Health Data Research UK [1] and collaboration 
between Novartis and National Health Service England to conduct a novel large scale clinical trial 
using healthcare system data [2]. It is vital therefore that we understand their utility in clinical trials 
in common chronic diseases, epilepsy being the exemplar in this paper.   
Routinely recorded data can be defined as data that are routinely recorded for specific, defined 
primary purposes, other than audit or research [3]. Data regarding clinical care are routinely 
documented in electronic medical records and stored in administrative healthcare databases in the 
UK [4, 5].   
Routinely recorded data have established use in retrospective observational studies such as record 
linkage population studies, but their use in Randomised Controlled Trials (RCTs) is less well 
established. RCTs remain the gold standard for assessing the efficacy and effectiveness of 
treatments in healthcare [6] and publicly funded, pragmatic RCTs typically provide longer-term 
outcome data to inform chronic disease management.  However, the majority of RCTs are time 
consuming and resource intensive as clinicians typically assess participants at clinic visits and record 
trial data on case report forms. If a trial is assessing outcomes that are important to participants, 
such as a core outcome set [7, 8], one might expect relevant data to be recorded routinely. 
Routinely recorded data have been used to inform judgements about the feasibility, sample size and 
recruitment targets in RCTs [9], measure certain participant outcomes [10-12] such as mortality and 
inform health economic analyses [13]. Routinely recorded data are a potential source of data for a 
wider range of clinical outcomes, and their use could greatly improve the efficiency of clinical 
research [5, 10, 14], reducing the burden to participants and researchers [15]. Furthermore, data 
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from non-clinical routine sources may inform outcomes beyond the standard RCT assessments of 
clinical efficacy and effectiveness. For example, cost data (such as use of healthcare resources) and 
socio-economic data (such as employment and means-tested benefits data) may inform health 
economic analyses and the assessment of the broader societal impact of healthcare interventions.  
Limitations in feasibility, accessibility and accuracy have been identified [16, 17]. For example, the 
accuracy of routinely recorded data in identifying incident cases may be reduced compared to 
prevalent cases which may impact on the utility of routinely recorded data to identify individuals 
with ‘new’ diagnoses, a frequent target group for RCTs. Furthermore, routinely recorded data may 
have limitations in identifying recurrent events compared to single events. For example, it may be 
expected that the identification of stroke would be of greater accuracy than the identification of 
seizure occurrences.   
The accuracy of diagnosis of epilepsy using routinely recorded healthcare data compared to 
independent review of patients’ medical records has been assessed [18]. However, there is scant 
evidence of the assessment of accuracy or agreement compared to standard methods of data 
collection employed in prospective research, such as the record of data on Case Report Forms 
(CRFs).  
Routinely recorded data are being used increasingly in prospective research, including RCTs, without 
evidence of an appraisal for this purpose [19]. An assessment of the attributes and agreement of 
routinely recorded data compared to data collected using standard prospective methods is therefore 




To assess the attributes and agreement between routinely recorded data and data collected using 
case report forms in a UK pragmatic RCT assessing antiepileptic drug treatments for individuals 





The case study RCT is the Standard and New Antiepileptic Drugs II (SANAD II (EudraCT No: 2012-
001884-64, ISRCTN Number: 30294119)) trial, a pragmatic, UK multicentre RCT assessing the clinical 
and cost effectiveness of selected antiepileptic drugs as first line treatments for newly diagnosed 
epilepsy.  
 
Individuals with newly diagnosed epilepsy participating in SANAD II, aged 16 years or older and with 
a minimum of 12 months follow-up were eligible for inclusion in this study. Participants were sent a 
study invitation via post and asked to sign a consent form. One further postal invitation was sent if 
there was no initial response. Routinely recorded data were retrieved from NHS Digital [20], which 
included data for episodes of patient contact with NHS secondary care in England and from The 
Secure Anonymised Information Linkage Databank (SAIL) [21], including access to data for episodes 
of patient contact with NHS secondary care and in selected cases primary care for patients in Wales. 
All datasets used clinical coding systems; the inpatient and outpatient datasets using the 
International Statistical Classification of Diseases and Related Health Problems (ICD) 10 [22], the 
primary care dataset using UK READ Codes [23] and the emergency datasets using unique coding 
systems. The study was reviewed and approved by the North of Scotland Research Ethics Service and 
Health Research Authority (29/01/16, REC reference: 16/NS/0007, Protocol number: UOL001183, 
IRAS project ID: 189002).  
 
To permit assessment of the attributes of routinely recorded data and agreement compared to data 
collected using case report forms, data variables relevant to each of the following aspects were 
identified or constructed from the available datasets: 
- The identification of individuals meeting the inclusion criteria and eligible for recruitment 
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o Variables included ‘Age’, ‘Date of First Ever Seizure’, ‘Date of Diagnosis of Epilepsy’ 
- The collection of data relevant to the baseline RCT assessment  
o Variables included ‘Classification of Seizures’, ‘Clinical Investigation Results’ 
- The collection of data relevant to the follow-up RCT assessments  
o Variables included ‘Date of First Follow-Up Seizure’, ‘Adverse Events’, ‘Planned and 
Unplanned Healthcare Attendances’ together with the constructed outcomes ‘Time 
to First Follow-Up Seizure’ and ‘Time to 12-Month Remission’ 
 
An algorithmic approach was developed for each variable, using knowledge of the coding systems, 
clinical behaviours and organisational pathways. Similar approaches utilising the clinical 
interpretation of routinely recorded data have previously been used in studies assessing seizures 
[24] and in other disease areas in the UK [25-27]. Diagnostic codes indicating the occurrence of 
relevant events were specified a priori and the ‘best-case’ dataset was used in the analysis, 
constructed using the available data from all relevant primary and secondary care routine datasets. 
Throughout the analyses the included participants were analysed as a complete cohort, without 
reference to antiepileptic drug (AED) prescribed or SANAD II study treatment arm. The algorithms 
developed for each variable together with the diagnostic codes are presented as Supplementary 
Figures 1-4 and Supplementary Tables 1-6. Figure 1 presents as an example the algorithm for the 
identification of seizure occurrence.  
Participants study data recorded using standard methods in SANAD II were retrieved. Data were 
captured on CRFs at baseline and regular follow-up intervals (3, 6, 9 and 12 months thereafter).  
Assessment of the attributes of routinely recorded data included identifying the degree of missing 
data compared to data collected using case report forms.    
A statistical assessment of agreement was completed. Bland Altman methods [28] were used to 
assess the agreement between paired continuous data and acceptable clinical limits of agreement 
were specified a priori, informed by clinical discussion. The Difference and Mean between datasets 
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were computed. Bland Altman Plots were constructed with the Difference variable plotted on the Y 
axis and the Mean variable plotted on the X axis. The mean of the Difference variable was plotted 
and the 95% confidence limits of agreement were calculated and discussed in the context of the 
specified acceptable clinical limits of agreement [28]. Time to event outcomes were assessed using 
Kaplan Meier curves and a Log Rank test was performed with P-value <0.05 indicating a statistically 
significant difference. To assess agreement between paired, nominal categorical datasets, cross 
tabulations were presented followed by calculation of Cohen’s kappa and a P<0.05 indicated the 
level of agreement defined by kappa being significant [29]. All analyses were performed in SPSS, 
Version 22.  
 
The STROBE Checklist is the most relevant, available research reporting checklist and has been 
referred to when drafting this manuscript, the summary flowchart included as an additional file.  
 




Four hundred and seventy participants in SANAD II were aged 16 years or older with a minimum of 
12 months follow-up, fulfilling the inclusion criteria (April 2016). Ninety eight participants provided 
consent to participate in this study, 55 males and 43 females with a mean age of 50. Demographics 
were similar for the 372 patients not providing consent. Routinely recorded data were requested for 
71 participants resident in England, with data available in inpatient, outpatient, emergency and 
critical care datasets and 27 participants resident in Wales, with data available in inpatient, 
outpatient, emergency datasets.  Primary care data were available for a subset of 23 participants 
resident in Wales.  
Table 1 summarises the attributes of the available data in primary and secondary care sources for 
selected variables in the 23 participants in whom data from both sources were available. As 
demonstrated, secondary care sources provide more complete data for identifying first seizure 
occurrence, whilst primary care sources provide more complete data regarding diagnosis of epilepsy 
and in addition, prescribing information. For the analyses presented in this paper, the ‘best case’ 
dataset has been used including available data from all sources.  
The results for each variable and outcome measure assessed are summarised in Table 2. Flowcharts 
summarising the identification of relevant data, Bland Altman plots and Kaplan Meier survival curves 
are presented in Supplementary Figures 6-34 and Supplementary Tables 7-14.  
Insert Table 1 
Variables Relevant to the Identification of Eligible Individuals and SANAD II Baseline Assessment 
Sixty two of the 98 included participants had a date (day, month and year) of first ever seizure 
occurrence recorded in SANAD II during the time period covered by the available routine data and 
were eligible for the assessment of ‘date of first ever seizure’. In the routine datasets a first ever 
seizure occurrence was identified in 23 of the 62 participants. The most common recorded codes 
were non-specific ‘seizure’ and ‘epilepsy’ codes. The most common ICD 10 code was ‘Unspecified 
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Convulsions (R568)’, emergency code ‘CNS Conditions – Epilepsy (HES 41, SAIL 17A)’ and READ codes 
‘Convulsion NOS (R003z)’ and ‘Had a Fit (IB63)’. 
Figure 2 shows a flowchart for the identification of ‘first ever seizures’ in routine datasets. Although 
sixteen participants had a relevant attendance within 48 hours of a seizure occurrence recorded in 
SANAD II, seizure could not be identified as the cause of the attendance due to inadequate or 
discrepant diagnostic codes. Codes included ‘CNS, Non-Epilepsy’ in the emergency datasets and 
‘Disorientation’ and ‘Confusion’ in the inpatient datasets. The Bland Altman Plot, Figure 3, 
demonstrates that when a date of first seizure is identified in the routinely collected data, 
agreement with data collected using CRFs is poor. The 95% confidence limits of agreement between 
the dates of first ever seizure are 145 and -313 days, well in excess of the specified 30 day clinically 
acceptable limit. The mean of the difference between the dates is -84, indicating that on average the 
date of first ever seizure is identified in the routinely collected data 84 days after the seizure is 
identified in the SANAD II dataset. Limiting the first ever seizures to ‘tonic-clonic’ seizures, the data 
were marginally more complete with seizures identified for 22 out of 43 participants with a tonic-
clonic seizure recorded in the SANAD II dataset, although agreement regarding the date of first 
tonic-clonic seizure occurrence remains poor.  
At the time of recruitment into SANAD II, using routinely collected data 41 of 78 participants met the 
criteria for diagnosis of epilepsy and agreement was poor for the ‘date of diagnosis of epilepsy’. 
Seizures could be classified in all participants using data retrieved from routinely recorded datasets, 
however, agreement was poor (Cohens Kappa 0.151, P=0.018) explained by the disproportionately 
large number of participants deemed ‘unclassified’ as a result of lack of clinical detail in the codes 
recorded.  
Variables and Outcomes Relevant to the Follow-Up in SANAD II 
Twenty two participants had first follow-up seizures identified using routinely collected datasets, 
compared to 61 participants using SANAD II data. The mean time to first follow-up seizure was 325 
days calculated using SANAD II data and 778 days calculated using routine data. Figure 4 presents 
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the Kaplan Meier Curve. Proportionally, a greater number of first follow-up tonic-clonic seizures 
were identified, 20 participants using routinely collected data compared to 35 using SANAD II.  
Data regarding adverse events were sparse in routine datasets and of 97 adverse events recorded in 
SANAD II only two were identifiable in routine datasets.          
Prescribing data were only available from the primary care dataset. Twenty-six ‘first AED 
prescriptions’ were identified, all prescription times being within the 90 day clinical limit of 
agreement with data recorded in SANAD II.   
Dates of episodes of outpatient planned and inpatient and emergency unplanned healthcare 
resource use had fewer missing data compared to clinical variables, for example 317 outpatient 
attendances were included in the SANAD II dataset, compared to 350 recorded in routinely collected 
data. Furthermore, the dates of attendance were within the acceptable clinical limits of agreement.   
For some variables additional data were recorded in the routinely recorded datasets that were not 
available in the SANAD II CRFs. For three participants in whom the CRF data indicated they were 
seizure free, additional seizures were identified in the routine datasets.  For one individual without 
an EEG result on the SANAD II CRF, the routine data indicated that they had had an EEG. Two 
participants of the 23 with available prescribing data in routine datasets were prescribed additional 
AEDs not recorded in the CRFs. Finally, data regarding AED adherence could be inferred from the 
routine datasets using frequency of repeat prescription, noting the assumptions made in reaching 
this result.    
Insert Table 2 
Insert Figure 2 
Insert Figure 3 





Routinely recorded data are increasingly being used in clinical trials to provide answers to important 
clinical questions. However, this study shows that for epilepsy, and potentially therefore for other 
chronic conditions it is not currently possible to identify important clinical events and outcomes in 
routinely recorded data in the UK. Therefore, their exclusive use is not a valid substitute for data 
collected using standard methods such as Case Report Forms completed at clinic visits or via 
telephone. There is an ongoing drive to incorporate routinely recorded data into RCTs in an effort to 
improve research efficiency and reduce the burden for participants [1, 2] and the results of this 
study, using epilepsy as the exemplar, raise potentially significant concerns about the suitability of 
routine data for this purpose.  
  
We assessed the use of routinely recorded data to identify individuals eligible for recruitment into a 
RCT for people with newly diagnosed epilepsy and to collect baseline, follow up and outcome data. 
Regarding seizure occurrence, it was not possible to identify baseline (pre-epilepsy diagnosis) 
seizures in the routinely collected data for 63% of patients, or seizures during follow up for 64%. 
When baseline seizures or follow up seizures were identified, there was poor agreement with dates 
recorded in the trial database. The date of first follow-up seizure identified was 86 days (mean) after 
the first follow-up seizure recorded in the trial database. Follow-up seizures could not be identified 
in the routine data, either because no event was documented at all, or because codes used did not 
indicate that seizure was the reason for attendance or admission. As a consequence, analysis of 
routinely recorded data grossly underestimates the outcomes ‘time to first seizure’ and ‘time to 12-




Similarly, a ‘diagnosis of epilepsy’ was identified in less than half of the participants using the 
routinely recorded data around the time of randomisation into SANAD II. It was also not possible to 
classify seizure types for the majority of participants due to inadequate coding and coding options. 
 
Specific codes labelling ‘adverse events’ were not recorded. Furthermore, healthcare attendances 
correlating with the dates of adverse events recorded in SANAD II were not identified. SANAD II 
participants self-reported more unplanned emergency attendances and fewer unplanned inpatient 
admissions, compared to those events identified in routinely recorded datasets. For these data, it 
may be more likely that the routinely recorded data are correct, and that recall bias is responsible 
for the discrepancy in the SANAD II dataset.  
 
Explanations for the results may include the inaccurate recording of codes in routinely recorded 
datasets or inaccurate initial clinical diagnosis of seizures and epilepsy. Furthermore, certain events 
may not have been ‘recordable’, for example if participants did not seek medical attention following 
seizure occurrence or if relevant codes or detail are not included in the available coding systems and 
routine datasets. Finally, patients with seizures may frequently be treated and then discharged from 
the emergency department, where diagnostic coding is not mandatory. This study report refers 
specifically to outcomes as applied to epilepsy, although it must be noted that in other disease areas 
similar results may not be found and these explanations may not apply. For example, disease areas 
where the diagnosis is more explicit, where the presentation is acute and where admission (rather 
than discharge from an emergency department) is more commonly required may be more likely to 
be more completely and accurately recorded in routine datasets. Examples may include ‘myocardial 
infarction’ or ‘stroke’.  
 
The results of this study have implications for the use of routinely recorded data in RCTs in patients 
with epilepsy. In SANAD II, exclusively using routinely recorded data would not have allowed reliable 
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identification of eligible individuals for recruitment, collection of baseline data or the collection of 
data for seizure and adverse outcomes [14, 30]. Furthermore, only 98 of 470 patients (21%) provided 
consent for their routine data to be retrieved. Notably, the 470 patients had already consented to 
participate in the SANAD II RCT.   
Whilst routinely recorded data could not be used alone to construct clinical outcomes, routine data 
could aid the identification of events, such as seizure occurrence or prescription changes, that had 
been missed, and these data remain important for assessing health service resource use for 
economic analyses [31]. However, the limitations in accessing these data, such as cost and lengthy 
application processes, would need to be considered [17]. 
Further research is urgently required to assess the attributes, additional benefits, feasibility and 
cost-effectiveness of accessing routinely recorded data during RCTs in the UK in epilepsy and other 
common disease areas. The ‘Studies Within A Trial’ (SWAT) approach, embedding methodological 
research within an existing prospective trial [32] could be suggested as the method to facilitate such 
research. For example, routinely recorded data could be requested for a subset of participants 
within existing RCTs. The analysis of such data, compared to the standard RCT methods, may directly 
inform the use of routine data in the ongoing RCT as well as inform future research.  
The ‘de-identified’ nature of primary care data, cost and poor geographical coverage were notable 
limitations. Development of the infrastructure to record national primary care data coverage is 
required, either through improved collaboration between existing routine data sources with 
individual-level data linkage or the development of national data sources, such as the NHS Digital 
General Practice Extraction Service [33]. Further, a number of countries have integrated healthcare 
systems allowing for national administrative healthcare databases, such as the Swedish Hospital 
Discharge Register, the Danish National Hospital Register and the Canadian Chronic Disease 
Surveillance System. In these examples it is possible to retrieve routinely recorded data from 
electronic medical records for individuals across hospital inpatient admissions and emergency care, 
outpatient clinic and primary care attendances. In the UK, standardisation of the coding systems 
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used in different care settings and between datasets and greater involvement of clinicians in the 
clinical coding process may improve the accuracy and completeness of clinical coding. A suggested 
proposed improvement could include the development of a national, integrated electronic health 
record for use in direct clinical care, with secondary uses in audit and research. Such a proposal 
would include direct clinician input and selection of diagnostic codes and would have significant 
potential for the improved recording of data and improved utility for the datasets in clinical practice 
and research.   
Whilst patients and the public are broadly supportive of data recording and sharing for healthcare 
research, concerns remain over confidentiality and potential abuses of data [34]. Public concerns 
regarding the sharing and linking of routinely recorded data will hamper future efforts to develop 
linked routinely recorded administrative databases, despite the likely benefits to individuals and the 
population. Further research is required with public engagement to define the issues of importance 
to members of the public and assess perspectives with regards the routine recording of data and 
subsequent use for secondary purposes including research.       
This study has notable limitations. The variables and constructed outcomes derived from the 
routinely recorded datasets were defined and extracted using algorithms developed for each 
comparison. There is a risk that relevant clinical events may not have been identified. To address this 
limitation and explore the data further, the routinely recorded data for each participant were 
examined in their entirety to identify additional relevant events. This process was feasible as a result 
of the small sample size. Furthermore, this study involved the retrospective identification of events 
in routinely recorded datasets and comparison to events identified in a study designed and 
completed using standard prospective methods. It must be acknowledged that the comparator study 
was not designed to be completed retrospectively using routinely recorded datasets and if this had 
been the case, alternative methodologies may have been employed.   
Substantial further development is now required to improve the utility of routinely recorded data in 
research. To improve the likelihood of significant progress, initiatives for development should 
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include collaboration from the government, National Health Service, researchers and perhaps most 
importantly acknowledging recent controversies, patients and the public; re-gaining their trust will 
be essential in realising the individual and population healthcare benefits of routinely recorded data. 
Examples of such work in progress include the European Health Data and Evidence Network [35], 
whose objectives include standardising real-world health data Europe-wide for purposes including 
research, Health Data Research UK [36] and the PED4PED initiative, a project aiming to improve 
outcomes for patients with epilepsy by linking data between primary, secondary and the emergency 
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Table 1: Summary of Primary and Secondary Care Data* 
Variable Total 
Participants 















First Ever Seizure (All Types) 
 
12 (52%) 10 (43%) 6 (26%) 6 (26%) 2 (8%) 
 
Diagnosis of Epilepsy (Baseline) 
 
18 (78%) 5** (22%) 5 (22%) 13*** (57%) 13 (57%) 
 
Date of First Follow-Up Seizure 
 
7 (30%) 3 (13%) 3 (13%) 4 (17%) 4 (17%) 
 
Date of AED First Prescription 
 
23 (100%) 0**** 0 23 (100%) 23 (100%) 
* For 23 participants in whom data from both primary and secondary care sources were available  
** Diagnosis made by record of two seizure episodes 
*** Diagnosis made by record of a code consistent with ‘diagnosis of epilepsy’ 

























Data Variables Relevant to the Identification of Eligible Individuals and Baseline Assessment in SANAD II 
 
 
First Ever Seizure (All Types) 62 62 (100%) 23 (37.1%) P=0.002 BA: -84.09  
(-313.12 – 144.94) 
30 Days 
First Ever Seizure (Tonic-Clonic) 62 43 (69.4%) 22 (35.5%) P=0.043 BA: -28.07  
(-123.72 – 67.58) 
30 Days 
Diagnosis of Epilepsy (Baseline) 78 78 (100%) 37 (47.4%) P=0.004 BA: 30.54  
(-106.17 – 167.25) 
30 Days 
Diagnosis of Epilepsy (All-Time) 81 81 (100%) 47 (58.0%) P=0.195 BA: -26.23 
(-294.10 – 241.64) 
30 Days 
Classification of Seizures 
(Baseline) 
37 37 (100%) 37 (100%) N/A CK: 0.151  
(P=0.018) 
N/A 
Classification of Seizures (All-
Time) 
47 47 (100%) 47 (100%) N/A CK: 0.123 
(P=0.019) 
N/A 
Clinical Investigations  
Magnetic Resonance Imaging  




Computed Tomography  









Data Variables Relevant to the Follow-Up in SANAD II 
 
 
Date of First Follow-Up Seizure 98 61 (62.2%) 22 (22.4%) P=0.024 BA: -86.26 
(-386.41 – 213.89) 
30 Days 
Date of First Follow-Up Tonic-
Clonic Seizure 
98 35 (35.7%) 20 (20.4%) P=0.374 BA: -9.20 
(-436.46 – 418.06) 
30 Days 
Date 12 Month Remission 
Achieved 
98 46 (46.9%) 74 (75.5%) P=0.004 BA: 34.24 
(-115.48 – 183.96) 
30 Days 
Date of AED First Prescription 26 26 25 P<0.001 BA: -19.76 
(-67.86 – 28.34) 
90 Days 
Adverse Events 97 97 2 - - - 
Planned Healthcare Attendances 
Baseline Assessment 
98 98 (100%) 87 (88.8%) P<0.001 BA: 1.67 
(-7.21 – 10.55) 
N/A 
Planned Healthcare Attendances 
Follow-Up Assessments 
350 350 (100%) 317 (90.6%) P<0.14 BA: 0.07 




94 52 (55.3%) 37 (39.4%) P=0.051 BA: 0.05 




94 12 (12.8%) 19 (20.2%) P=0.098 BA: -0.02 
(-0.72 – 0.68) 
N/A 
 














Days to First Follow-Up Seizure 98 61 (62.2%) 22 (22.4%) 325 (258-393) 751 (680-822) P<0.001 
Days to 12 Month Remission 98 46 (46.9%) 74 (75.5%) 567 (515-618) 393 (375-410) P<0.001 
*Paired T Test (normally distributed data), Wilcoxon Signed Rank (non-normally distributed data) 
**Bland Altman Methods (BA) (continuous data) = Mean (lower 95% confidence limit of agreement – upper 95% confidence 
limit of agreement) 
**Cohen Kappa (CK) (categorical data) = 0.01–0.20 as none to slight agreement, 0.21–0.40 as fair, 0.41– 0.60 as moderate, 
0.61–0.80 as substantial, and 0.81–1.00 as almost perfect agreement 
*** Acceptable clinical limit of agreement specified a priori  
**** Log Rank Test 
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21 Medical or Dental 
A&E  
22 General Practitioner 
23 Bed Bureau 
24 Consultant Clinic 
28 Other 
 
EMERGENCY Datasets PRIMARY CARE Dataset 
Relevant Medical Speciality 
 
Review ICD Codes:  
 
Definite Seizure Probable Seizure 
‘Definite’ seizure code 
listed in first 
diagnostic position 
‘Definite’ seizure code 










Review Seizure Codes: 
Seizure code listed in the 
first diagnostic position 
Review Seizure Codes: 
Seizure code listed  
Review Dates of Outpatient 
Neurological Appointments   
No correlating Neurology 
outpatient appointment 
within one month of date of 
































Routine: No evidence of seizure or relevant attendances with 









Routine: Relevant attendances, missing diagnostic code: 
- A&E / EDDS: 12 
- APC / PEDW: 0  
  
16 Participants 
Routine: Relevant attendances, inadequate or discrepant 
diagnostic code not meeting the criteria for seizure occurrence: 
- A&E / EDDS: 16  





Relevant attendances for dates of first seizure identified: 
- HES A&E:  12 SAIL EDDS: 8 
- HES APC:  10 SAIL PEDW: 5 
SAIL GP:  6 
Attendances recorded in 1 dataset (7 participants), 2 datasets 





Figure 3: Date of First Ever Seizure: Bland Altman Plot 
Mean -84.09 
Upper 95% Confidence Limit of Agreement 144.94 







Figure 4: Kaplan Meier Curve: The Time to First Follow-Up Seizure 
 
1 = SANAD II Dataset 
2 = Routine Dataset 
 
